TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26431300

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 98
Study: 23683372

Group type: EXPERIMENTAL
Intervention: Familial risk information (intervention group)
Number of subjects: 1174

Group type: COMPARATOR
Intervention: General tailored diabetes prevention information (control group)
Number of subjects: 1174
Study: 22010544

Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted influenza vaccine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Influenza vaccine without MF59 adjuvant
Number of subjects: 106
Study: 18647573

Group type: EXPERIMENTAL
Intervention: Hydrochlorate of raloxifene
Number of subjects: 57

Group type: COMPARATOR
Intervention: Hormone replacement therapy (Control)
Number of subjects: 57
Study: 16463410

Group type: EXPERIMENTAL
Intervention: Primary Therapist Model (PTM)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Traditional Treatment Model (TTM)
Number of subjects: 111
Study: 12771254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: 50 mg/d pregabalin
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: 150 mg/d pregabalin
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: 300 mg/d pregabalin
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: 600 mg/d pregabalin
Number of subjects: 453
Study: 11026123

Group type: EXPERIMENTAL
Intervention: 0.015% BAC
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Negative feedback
Number of subjects: 104

Group type: COMPARATOR
Intervention: 0% BAC and 0.03% BAC
Number of subjects: 104
Study: 9192152

Group type: EXPERIMENTAL
Intervention: Adding sugar to tea and coffee
Number of subjects: 187

Group type: COMPARATOR
Intervention: Excluding sugar from tea and coffee
Number of subjects: 187
Study: 1301409

Group type: EXPERIMENTAL
Intervention: Acetyl‐L‐carnitine (3 x 1 g daily for 1 month) + methylprednisolone (50 mg daily for 14 days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3541062

Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2‐triacetin gel (Prepidil gel) endocervically
Number of subjects: 73

Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 73
Study: 30169539

Group type: EXPERIMENTAL
Intervention: Usual care plus person-centred telephone-support intervention
Number of subjects: 221

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 221
Study: 26998695

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 148
Study: 24825595

Group type: EXPERIMENTAL
Intervention: Total oxidant status (TOS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Oxidative stress index (OSI)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Total antioxidant status (TAS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Prolidase activity
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Total antioxidant status (TAS) in patients with lung involvement
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Total antioxidant status (TAS) in patients with gastrointestinal tract involvement
Number of subjects: 38
Study: 23130488

Group type: EXPERIMENTAL
Intervention: Personal health record booklet (PHRB) with health education for CVD information and self-monitoring practice
Number of subjects: 204

Group type: COMPARATOR
Intervention: Regular follow-up and routine blood pressure recording
Number of subjects: 204
Study: 20554740

Group type: EXPERIMENTAL
Intervention: Atenolol, bisoprolol, or metoprolol (beta-blockers)
Number of subjects: 45
Study: 18577730

Group type: EXPERIMENTAL
Intervention: Home BP monitoring and secure patient Web site training only
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Home BP monitoring and secure patient Web site training plus pharmacist care management
Number of subjects: 778

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Home BP monitoring and Web training plus pharmacist care
Number of subjects: 778
Study: 15894434

Group type: EXPERIMENTAL
Intervention: Readiness for treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health problems and deviant family/peers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demographic variables and specific substances used
Number of subjects: 0
Study: 11818109

Group type: EXPERIMENTAL
Intervention: Early laparoscopy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional method based on clinical observation
Number of subjects: 110
Study: 10634670

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no enalapril)
Number of subjects: 13
Study: 7593872

Group type: EXPERIMENTAL
Intervention: Food provision
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 177

Group type: COMPARATOR
Intervention: Standard behavioral treatment
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Weight loss success
Number of subjects: 177
Study: 2047768

Group type: EXPERIMENTAL
Intervention: Epirubicin (E)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Epirubicin + Verapamil (E + V)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Before instillation therapy
Number of subjects: 75
Study: 7261638

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31232370

Group type: EXPERIMENTAL
Intervention: Î² blockers
Number of subjects: 0
Study: 29658235

Group type: EXPERIMENTAL
Intervention: Modified Bianchi orchiopexy (MBO)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Traditional surgery (control)
Number of subjects: 82
Study: 25613214

Group type: EXPERIMENTAL
Intervention: Single-drug (doxorubicin) chemoembolization
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Double-drug (doxorubicin and mitomycin C) chemoembolization
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Triple-drug (doxorubicin, mitomycin C, and gemcitabine) chemoembolization
Number of subjects: 162
Study: 24300505

Group type: EXPERIMENTAL
Intervention: Prehospital thrombolysis using intravenous recombinant tissue plasminogen activator (iv rtPA, alteplase, Actilyse) with STEMO care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular care without STEMO
Number of subjects: 0
Study: 21119532

Group type: EXPERIMENTAL
Intervention: Weight loss (WL)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Weight loss combined with aerobic exercise (WL + EX)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 38
Study: 20014602

Group type: EXPERIMENTAL
Intervention: Forehead reflectance sensor (Max-Fast)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional digital sensor (finger sensor)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Forehead reflectance sensor (Max-Fast) at maximum PEEP
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional digital sensor (finger sensor) at maximum PEEP
Number of subjects: 16
Study: 16507428

Group type: EXPERIMENTAL
Intervention: High doses of enalapril (mean: 42 ± 19.3 mg/day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard doses of enalapril (mean: 17.9 ± 4.3 mg/day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Low baseline hematocrit (Hct)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Low systolic blood pressure
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Baseline Hct
Number of subjects: 160
Study: 15374786

Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin
Number of subjects: 1570

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1570
Study: 11182177

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (no tablet)
Number of subjects: 81
Study: 9862942

Group type: EXPERIMENTAL
Intervention: Omeprazole plus Amoxicillin and Clarithromycin (20 mg omeprazole twice daily, 1000 mg amoxicillin twice daily, 500 mg clarithromycin twice daily for 7 days)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Omeprazole alone (for 7 days)
Number of subjects: 328
Study: 7956347

Group type: EXPERIMENTAL
Intervention: Older women (above 50 years old)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Younger women (below 30 years old)
Number of subjects: 2
Study: 2675435

Group type: EXPERIMENTAL
Intervention: Methohexital (Brietal)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 36
Study: 1109518

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study: 28475549

Group type: EXPERIMENTAL
Intervention: Inertia Barbell Training Group (IBTG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal Barbell-Training Group (NBTG)
Number of subjects: 30
Study: 31319846

Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 428
Study: 28526386

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/d) plus pyridoxine (80 mg/d)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/d)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 95
Study: 26484426

Group type: EXPERIMENTAL
Intervention: Female caregivers
Number of subjects: 289

Group type: COMPARATOR
Intervention: Male caregivers
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Caregiving impact on finances
Number of subjects: 289
Study: 23771563

Group type: EXPERIMENTAL
Intervention: Human albumin (2.5 g) in the extracorporeal prime
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (protein free)
Number of subjects: 20
Study: 21600062

Group type: EXPERIMENTAL
Intervention: Supervised exercise training 3 times a week for 12 weeks, followed by 3 sessions per week of home exercise for 12 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 34
Study: 19637098

Group type: EXPERIMENTAL
Intervention: Ticagrelor (AZD6140)
Number of subjects: 151
Study: 16684825

Group type: EXPERIMENTAL
Intervention: Teriparatide 37 microg sc daily (group 2)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combination therapy (group 3)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Alendronate 10 mg daily (group 1)
Number of subjects: 63
Study: 15672789

Group type: EXPERIMENTAL
Intervention: Polymyxin B immobilized fibers (PMX-F)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 120
Study: 11743672

Group type: EXPERIMENTAL
Intervention: Sevoflurane (2 % endtidal) in 60 % N2O/O2
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol (3 mg/kg and 10 mg/kg/h) in 60 % N2O/O2
Number of subjects: 50
Study: 9215505

Group type: EXPERIMENTAL
Intervention: Dating violence prevention curriculum (five-session program)
Number of subjects: 193

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 193
Study: 7964913

Group type: EXPERIMENTAL
Intervention: Intranasal sumatriptan 20 mg
Number of subjects: 455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study: 3580514

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg q.i.d. for 4 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Standing posture
Number of subjects: 9
Study: 31651838

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) with low-level laser (Ga-Al-As, 808 nm, 100 mW)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham group (simulated laser irradiation)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 72
Study: 27789136

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sedentary Time
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall PA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sedentary Behavior
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Steps/d
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Light PA
Number of subjects: 50
Study: 25486494

Group type: EXPERIMENTAL
Intervention: Albendazole (400mg per day for 3 days)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 23408591

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections (2 autologous injections over 2 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Focused extracorporeal shock wave therapy (ESWT) (3 sessions of 2400 impulses at 0.17-0.25 mJ/mm² per session)
Number of subjects: 46
Study: 21515999

Group type: EXPERIMENTAL
Intervention: Web-based education program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booklet education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18644934

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement containing vitamin A, folic acid, iron, zinc, and 11 other nutrients
Number of subjects: 3927

Group type: COMPARATOR
Intervention: Vitamin A alone (control)
Number of subjects: 3927

Group type: EXPERIMENTAL
Intervention: Folic acid plus iron
Number of subjects: 3927

Group type: EXPERIMENTAL
Intervention: Folic acid plus iron plus zinc
Number of subjects: 3927

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 3927
Study: 17121726

Group type: EXPERIMENTAL
Intervention: Huperzine A (0.3 mg/2 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (2 ml)
Number of subjects: 30
Study: 12527666

Group type: EXPERIMENTAL
Intervention: Mitral annular calcification
Number of subjects: 885

Group type: COMPARATOR
Intervention: Control group (no mitral annular calcification)
Number of subjects: 885
Study: 10648365

Group type: EXPERIMENTAL
Intervention: 1 mg of nebulised budesonide (Bud)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 161
Study: 8870326

Group type: EXPERIMENTAL
Intervention: 50 mg of diclofenac
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50 mg of diclofenac + 10 mg of prednisolone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1892197

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 6349134

Group type: EXPERIMENTAL
Intervention: Cytoplasmatic therapy with macromolecular substances
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31593577

Group type: EXPERIMENTAL
Intervention: Sexually active AGYW
Number of subjects: 2276

Group type: EXPERIMENTAL
Intervention: Formerly married AGYW
Number of subjects: 2276

Group type: EXPERIMENTAL
Intervention: AGYW with children
Number of subjects: 2276

Group type: EXPERIMENTAL
Intervention: AGYW with anxiety and depression symptoms
Number of subjects: 2276

Group type: EXPERIMENTAL
Intervention: AGYW engaged in sex work in the past six months
Number of subjects: 2276

Group type: EXPERIMENTAL
Intervention: AGYW experiencing economic deprivation
Number of subjects: 2276
Study: 29304798

Group type: EXPERIMENTAL
Intervention: Short message service (SMS) reminders for dosing of artemether-lumefantrine (AL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care without SMS reminders
Number of subjects: 0
Study: 26779990

Group type: EXPERIMENTAL
Intervention: High-power holmium laser lithotripsy (HP-HLL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ultrasonic lithotripsy (US-L)
Number of subjects: 70
Study: 23360079

Group type: EXPERIMENTAL
Intervention: RLA + HBOT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LA + HBOT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + HBOT
Number of subjects: 0
Study: 22354739

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Fingolimod (both doses)
Number of subjects: 171
Study: 20150299

Group type: EXPERIMENTAL
Intervention: Self-efficacy, problem solving, and social-environmental support
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Medication-taking behaviors
Number of subjects: 463
Study: 17392946

Group type: EXPERIMENTAL
Intervention: Stress management intervention
Number of subjects: 17

Group type: COMPARATOR
Intervention: Wait listed control
Number of subjects: 17
Study: 11408508

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/d
Number of subjects: 7705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene (both dosages)
Number of subjects: 7705
Study: 9259905

Group type: EXPERIMENTAL
Intervention: Terbutaline pump
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline pump
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 42
Study: 8284109

Group type: EXPERIMENTAL
Intervention: EPO 150 U/kg s.c. twice weekly for 6 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 44
Study: 3565967

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate
Number of subjects: 24
Study: 31652025

Group type: EXPERIMENTAL
Intervention: Lateral pararectal stoma placement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transrectal stoma placement
Number of subjects: 60
Study: 29319910

Group type: EXPERIMENTAL
Intervention: Nicotine (21 mg transdermal)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg oral)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Mecamylamine (30 mg oral)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 28002201

Group type: COMPARATOR
Intervention: TX-004HR 4 μg
Number of subjects: 72

Group type: COMPARATOR
Intervention: TX-004HR 10 μg
Number of subjects: 72

Group type: COMPARATOR
Intervention: TX-004HR 25 μg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 26229448

Group type: EXPERIMENTAL
Intervention: Cardioaspirin + Aterofisiol
Number of subjects: 214

Group type: COMPARATOR
Intervention: Cardioaspirin + placebo
Number of subjects: 214
Study: 24155873

Group type: EXPERIMENTAL
Intervention: Graded exercise treatment
Number of subjects: 10
Study: 22114896

Group type: EXPERIMENTAL
Intervention: Sufficiently controlled asthma
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Strictly controlled asthma
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Strictly controlled asthma based on exhaled nitric oxide
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Internet-based asthma monitoring system
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Societal costs (medication, other healthcare, productivity)
Number of subjects: 720
Study: 18772602

Group type: EXPERIMENTAL
Intervention: PTRA + IVBT
Number of subjects: 71

Group type: COMPARATOR
Intervention: PTRA
Number of subjects: 71
Study: 16996876

Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rhythm control
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Previous myocardial infarction
Number of subjects: 16
Study: 12887537

Group type: EXPERIMENTAL
Intervention: Endoluminal repair of the thoracic aorta
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional surgical repair
Number of subjects: 0
Study: 11049956

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (0.5, 1, or 2 microg/kg/min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.5, 1, or 2 microg/kg/min)
Number of subjects: 9
Study: 8849376

Group type: EXPERIMENTAL
Intervention: rHuIL‐1RI at 1,000 micrograms/m2/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: rHuIL‐1RI at smaller doses (125, 250, 500 micrograms/m2/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: rHuIL‐1RI (all doses)
Number of subjects: 23
Study: 1317234

Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg p.o.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg p.o.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31757774

Group type: EXPERIMENTAL
Intervention: ETVAX (5·5 × 10^10 cells, 2·5 × 10^10 cells, or 1·25 × 10^10 cells) with or without dmLT (2·5 μg, 5·0 μg, or 10·0 μg)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: ETVAX with dmLT
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: ETVAX
Number of subjects: 430
Study: 29533716

Group type: EXPERIMENTAL
Intervention: Nanohybrid composite (Ceram X duo)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nanofilled resin composite (Filtek Supreme XT)
Number of subjects: 34
Study: 27556488

Group type: EXPERIMENTAL
Intervention: Watermelon (WM) puree, 980 mL/day for 2 weeks, containing 0.2 gm/kg carbohydrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbohydrate beverage, 6% carbohydrate, consumed every 15 min during cycling trials
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Watermelon (WM) puree
Number of subjects: 20
Study: 25007060

Group type: EXPERIMENTAL
Intervention: Parent and teacher healthy lifestyle role-modeling program
Number of subjects: 28

Group type: COMPARATOR
Intervention: Attention control safety curriculum (Control)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (parents)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control children
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Teachers' influence
Number of subjects: 28
Study: 22674892

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise program (lower extremity strengthening, stretching, range of motion, balance and agility, and aerobic exercises)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise program
Number of subjects: 152
Study: 20728652

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (0.08 g/dl)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23